Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melanie Diaz

Nurse Practitioner New Hyde Park, NY Nurse Practitioner

NPI 1073631610 CMS profile 10650127

27005 76Th Ave, New Hyde Park, NY 11040

Open in the dashboard

General payments

$7,719

291 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melanie Diaz of New Hyde Park, NY is reported in the CMS Open Payments database as having received $7,719 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,641 65
2024 General $2,023 78
2023 General $2,077 58
2022 General $810 40
2021 General $1,169 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melanie Diaz
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Melanie Diaz were reported at $1,641. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Melanie Diaz Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,169 $135 $40–$426 $132
2022 $810 $152 $48–$470 $149
2023 $2,077 $166 $54–$529 $160
2024 $2,023 $173 $55–$556 $164
2025 $1,641 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $724 26 payments
  2. Merck Sharp & Dohme Corporation $416 16 payments
  3. Daiichi Sankyo Inc. $414 20 payments
  4. Novartis Pharmaceuticals Corporation $384 21 payments
  5. AstraZeneca Pharmaceuticals LP $377 8 payments
  6. Pharmacosmos Therapeutics Inc. $368 14 payments
  7. Alexion Pharmaceuticals, Inc. $365 14 payments
  8. Incyte Corporation $282 10 payments
  9. Seattle Genetics, Inc. $254 5 payments
  10. Gilead Sciences, Inc. $242 7 payments
  11. Other $3,893 150 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,383 287 payments
  2. Education $336 4 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $355 14 payments
  2. MONOFERRIC $347 13 payments
  3. DARZALEX $346 14 payments
  4. TECVAYLI $249 10 payments
  5. ULTOMIRIS $233 12 payments
  6. MONJUVI $207 9 payments
  7. OXBRYTA $206 8 payments
  8. TALVEY $192 7 payments
  9. LIBTAYO $187 2 payments
  10. INJECTAFER $185 9 payments
  11. Other $5,776 225 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

113

Median for Nurse Practitioner: 389

Drug cost

$853,674

Median for Nurse Practitioner: $21,885

Branded share of claims

40.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pomalyst Pomalidomide Brand 24 $475,368
Revlimid Lenalidomide Brand 22 $259,937
Lenalidomide Generic 11 $117,481
Fluconazole Generic 12 $320
Acyclovir Generic 21 $306
Ondansetron Hcl Generic 23 $262

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 45 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REBLOZYL
  • E.R. Squibb & Sons, L.L.C. $127
  • Celgene Corporation $16
$143 — —
RYBREVANT
  • Janssen Scientific Affairs, LLC $87
$87 — —
MONOFERRIC
  • Pharmacosmos Therapeutics Inc. $78
$78 — —
TECVAYLI
  • Janssen Biotech, Inc. $71
$71 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 45 with Patron

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record